MARIA TERESA
BERNAL DEL CASTILLO
Profesora Asociada en CC. Salud - LOSU
Hospital Clinic Barcelona
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Clinic Barcelona (15)
2023
-
Genomics improves risk stratifi cation of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials
Haematologica, Vol. 108, Núm. 4, pp. 969-980
2022
-
Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry
Leukemia Research, Vol. 115
-
Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD
Therapeutic Advances in Hematology, Vol. 13
-
Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria
Leukemia Research, Vol. 116
2021
-
Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials
Hematological Oncology, Vol. 39, Núm. 4, pp. 529-538
2019
-
An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens
Leukemia and Lymphoma, Vol. 60, Núm. 4, pp. 1030-1035
2018
-
Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55–65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia
Leukemia Research, Vol. 68, pp. 79-84
-
Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy
Leukemia, Vol. 32, Núm. 1, pp. 21-29
2015
-
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: Results from the Spanish registry
Leukemia, Vol. 29, Núm. 9, pp. 1875-1881
-
Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score
Leukemia Research, Vol. 39, Núm. 1, pp. 52-57
2014
-
Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: Final results of the PETHEMA ALL-AR-03 trial
Journal of Clinical Oncology, Vol. 32, Núm. 15, pp. 1595-1604
2013
2012
-
The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome
Leukemia Research, Vol. 36, Núm. 3, pp. 287-292
2011
-
Cytogenetic risk stratification in chronic myelomonocytic leukemia
Haematologica, Vol. 96, Núm. 3, pp. 375-383
2006
-
Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: Results of a Spanish prospective cooperative protocol
Biology of Blood and Marrow Transplantation, Vol. 12, Núm. 2, pp. 172-183